References in periodicals archive ?
Pharmaceutical company Janssen Pharmaceutical Companies reported on Tuesday the receipt of US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults.
Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the Company's investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 60 years or older.
[USPRwire, Fri Aug 30 2019] Respiratory syncytial virus infection is highly contagious.
[ClickPress, Fri Aug 30 2019] Respiratory syncytial virus infection is highly contagious.
The "World Respiratory Syncytial Virus (RSV) Diagnostic Market - Opportunities and Forecasts, 2017 - 2023" report has been added to ResearchAndMarkets.com's offering.
Respiratory syncytial virus is one of the common causes of acute respiratory tract infections among children.
(4.) Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al.; Respiratory Syncytial Virus Global Epidemiology Network.
Laboratory testing trends for respiratory syncytial virus, 2007-2011.
Respiratory syncytial virus outbreaks of epidemic levels occur yearly at predictable times.
Respiratory syncytial virus leads to approximately 3,400,000 hospital admissions and at least 66,000 deaths each year and 99% of these deaths occur in developing countries (4).
In a study of 395 otherwise healthy premature infants who were randomized to receive palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis or placebo and followed for 6 years, 14% of the 199 infants in the RSV prevention group had parent-reported asthma, compared with 24% of the 196 in the placebo group (absolute risk reduction, 9.9%).

Full browser ?